Search results for "Patients"

showing 10 items of 962 documents

The Effect of Age, Gender, and Insertion Site on Marginal Bone Loss around Endosseous Implants: Results from a 3-Year Trial with Premium Implant Syst…

2014

Objectives.The goal of this study was to evaluate bone changes around endosseous implants in partially edentulous patients.Materials and Methods.A total of 632 two-stage implants were placed in 252 patients. The implants had straight emergence profile, ZirTi surface, 3.3 to 5 mm diameter, and 8.5 to 13 mm length. Bone levels were assessed on orthopantomography immediately after surgery and after 36 months and marginal bone loss (MBL) was calculated from their difference.Results.Cumulative survival rate was 98.73%. Overall MBL was 0.8 mm ± 0.03 (mean ± SEM). Higher MBL was observed around implants in the maxilla than in the mandible (P<0.007). A relation between implant diameter and MBL (…

MaleArticle SubjectRadiographyAlveolar Bone Losslcsh:MedicineDentistryInsertion sitechemical and pharmacologic phenomenaComorbidityGeneral Biochemistry Genetics and Molecular BiologyAge DistributionDental Implants Single-ToothPostoperative ComplicationsOlder patientsRisk FactorsMedicineDental Implantation Endosseous EndodonticHumansEndosseous implantsDental Restoration FailureSex DistributionOrthodonticsGeneral Immunology and Microbiologybusiness.industryIncidence (epidemiology)IncidenceJaw Edentulous Partiallylcsh:RMandibleGeneral MedicineDental Marginal AdaptationMiddle Agedbacterial infections and mycosesCausalityRadiographyTreatment OutcomeItalyMaxillaClinical StudyFemaleImplantbusinessBioMed Research International
researchProduct

Dental care protocol based on visual supports for children with autism spectrum disorders

2015

Background : Subjects with Autism Spectrum Disorders (ASDs) have often difficulties to accept dental treatments. The aim of this study is to propose a dental care protocol based on visual supports to facilitate children with ASDs to undergo to oral examination and treatments. Material and Methods : 83 children (age range 6-12 years) with a signed consent form were enrolled; intellectual level, verbal fluency and cooperation grade were evaluated. Children were introduced into a four stages path in or der to undergo: an oral examination (stage 1), a professional oral hygiene session (stage 2), sealants (stage 3), and, if necessary, a restorative treatment (stage 4). Each stage came after a vi…

MaleAutism Spectrum DisorderOdontologíaOral hygieneClinical ProtocolsmedicineVerbal fluency testHumansStage (cooking)Association (psychology)ChildGeneral DentistryDental Care for ChildrenAudiovisual Aidsbusiness.industryDental Care for ChildrenResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in DentistryCiencias de la saludTest (assessment)OtorhinolaryngologyAutism spectrum disorderUNESCO::CIENCIAS MÉDICASAutismPatient ComplianceSurgeryFemalebusinessPsychologyClinical psychologyMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleBRCA1 gene Founder mutation Haplotype analysis Hereditary breast and ovarian cancer Sicilian patientsSettore MED/06 - Oncologia MedicaGenetic counselingPopulationDNA Mutational AnalysisGenes BRCA1Single-nucleotide polymorphismBreast NeoplasmsBiologyBRCA1 geneHaplotype analysiHumansAlleleeducationAllelotypeFounder mutationSicilyGeneticsOvarian Neoplasmseducation.field_of_studyHaplotypeHematologylanguage.human_languageFounder EffectPedigreeOncologyHaplotypesHaplotype frequencylanguageFemaleSicilianGene DeletionFounder effectGenetic counselingMicrosatellite Repeats
researchProduct

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease : results from the EUROASPIRE IV …

2018

Background: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. Methods: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline a…

MaleCardiac & Cardiovascular SystemsCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisCoronary DiseaseDisease030204 cardiovascular system & hematology0302 clinical medicineOlder patientsMedicine030212 general & internal medicineguidelinesEUROASPIRE1102 Cardiorespiratory Medicine and Haematologyhealth care economics and organizationsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Framingham Risk ScoreSecondary preventionASSOCIATIONMiddle AgedhumanitiesCoronary heart diseaseEuropeDENSITY-LIPOPROTEIN CHOLESTEROLPractice Guidelines as TopicTRIALFemaleGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary prevention ; guidelines ; cost-effectiveness ; coronary heart disease ; EUROASPIREsecondary preventionmedicine.drugINTERVENTIONSmedicine.medical_specialtyEZETIMIBEGuidelinesEVENTS03 medical and health sciencesEzetimibeInternal medicineHumansIn patientcoronary heart diseaseBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.cost-effectivenessMETAANALYSISAgedScience & Technologybusiness.industryDecision TreesSMOKING-CESSATIONCoronary heart diseaseTHRESHOLDSCardiovascular System & HematologyCardiovascular System & CardiologySmoking cessationCost-effectivenessbusinessSTATIN TREATMENT
researchProduct

Undetectable high-sensitivity troponin in combination with clinical assessment for risk stratification of patients with chest pain and normal troponi…

2020

Background Undetectable high-sensitivity cardiac troponin (hs-cTn) in a single determination upon admission may rule out acute coronary syndrome. We investigated undetectable hs-cTnT (<detection limit; <5 ng/l) together with clinical risk scores (GRACE, TIMI, HEART and a previously published simple score), for one-year outcomes in patients with chest pain and normal hs-cTnT (<99th percentile; <14 ng/l) upon admission. Methods This study was a retrospective design involving 2254 consecutive patients (July 2016–November 2017). The primary endpoint was one-year death or acute myocardial infarction; the secondary endpoint added unstable angina requiring revasculariz…

MaleChest PainAcute coronary syndromemedicine.medical_specialtyCardiac troponinmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest painRevascularizationRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumans030212 general & internal medicineRetrospective StudiesInpatientsbiologybusiness.industryUnstable anginaGeneral MedicineMiddle AgedPrognosismedicine.diseaseTroponinTroponinHigh sensitivity troponinRisk stratificationbiology.proteinCardiologyFemalemedicine.symptomEmergency Service HospitalCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Heart Journal. Acute Cardiovascular Care
researchProduct

Characteristics and Outcomes of Patients Hospitalized With Suspected Acute Coronary Syndrome in Whom the Diagnosis is not Confirmed

2018

Patients admitted with suspected acute coronary syndrome (ACS) in whom the diagnosis is not confirmed are poorly characterized. In a contemporary registry of consecutive patients hospitalized with suspected ACS as the primary diagnosis, we assessed characteristics on admission and in-hospital and 6-month mortality of patients discharged with other diagnoses and compared this subgroup with true ACS patients. Of 2557 patients included, 9.0% were discharged with a non-ACS diagnosis such as nonspecific chest pain, myopericarditis, stress cardiomyopathy, hemodynamic disturbances, heart failure, myocardial, pulmonary or valvular disease, or others. Compared with true ACS patients, those with othe…

MaleChest PainAcute coronary syndromemedicine.medical_specialtyCardiomyopathyHemodynamics030204 cardiovascular system & hematologyCoronary AngiographyChest painRisk AssessmentDiagnosis DifferentialElectrocardiography03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansHospital MortalityProspective StudiesRegistries030212 general & internal medicineAcute Coronary SyndromeMedical diagnosisAgedInpatientsbusiness.industryMortality rateMiddle AgedPrognosismedicine.diseaseHospitalizationSurvival RateSpainHeart failureCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesMyopericarditisThe American Journal of Cardiology
researchProduct

Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey

2016

The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Background The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Methods We enrolled 2,557 CLD consecutive patients in 16 Italian liver units in 2014. Results HBV etiology accounted for 513 (20.2%) cases, alone in 439 and associated with HCV and/or alcohol abuse in 74. Of these 513, 11.9% were anti-HDV-positive and 7.2% HBeAg-positive. HCV alone was responsible for 50.3% of CLD and with alcohol abuse for 5.9%. HCV RNA was detec…

MaleCirrhosisAlcohol abuseGastroenterology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseSurveys and QuestionnairesEpidemiologyOutpatients80 and overSurveys and QuestionnaireChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Adolescent; Adult; Aged; Aged 80 and over; Alcoholism; Carcinoma Hepatocellular; Female; Genotype; Hepatitis B; Hepatitis C; Humans; Inpatients; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Outpatients; Surveys and Questionnaires; Young Adult; Hepatology; Gastroenterology030212 general & internal medicineYoung adultHCCChronic liver diseasesChronic hepatitisAged 80 and overMedicine (all)Liver NeoplasmsChronic liver diseaseGastroenterologyvirus diseasesOutpatientHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver Neoplasm030211 gastroenterology & hepatologyFemaleInpatientHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentGenotypeLiver CirrhosiChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Medicine (all); Hepatology; Gastroenterology03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedInpatientsHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesLiver cirrhosisEtiologyChronic hepatitibusiness
researchProduct

The influence of smoking status on exhaled breath profiles in asthma and COPD patients

2021

Breath analysis using eNose technology can be used to discriminate between asthma and COPD patients, but it remains unclear whether results are influenced by smoking status. We aim to study whether eNose can discriminate between ever- vs. never-smokers and smoking &lt

MaleCopd patientsPharmaceutical ScienceeNoseAnalytical ChemistryPulmonary Disease Chronic Obstructive0302 clinical medicineDrug DiscoveryElectronic Nose0303 health sciencesCOPDConfoundingfood and beveragesMiddle AgedBreath Testsexhaled breathChemistry (miscellaneous)ExhalationMolecular MedicineSmoking statusFemaleAdultmedicine.medical_specialtySmoking habitPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlesmokinglcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryInternal medicinemedicineHumansCOPDPhysical and Theoretical Chemistry030304 developmental biologyAsthmaVolatile Organic Compoundsbusiness.industryfungiOrganic Chemistryasthmamedicine.diseaserespiratory tract diseasesCross-Sectional Studies030228 respiratory systemBreath gas analysisROC CurveAsthma COPD eNose Exhaled breath SmokingCase-Control Studiesbusiness
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct